Cytophage Technologies Ltd.
CYTO.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.00% | 8.92% | -11.13% | 12.35% | 71.32% |
| Total Depreciation and Amortization | -26.65% | 39.32% | -2.15% | 2.92% | -4.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.18% | -54.72% | 645.45% | 64.13% | -100.93% |
| Change in Net Operating Assets | -83.50% | -41.53% | 358.75% | -9.09% | 108.78% |
| Cash from Operations | -29.15% | 6.19% | 14.86% | 16.32% | 51.44% |
| Capital Expenditure | 100.00% | 96.92% | 73.18% | 53.16% | -1,132.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 100.00% | 99.05% | 12.90% | 53.16% | -109.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -369.31% | 137.13% | 25.84% | 11.44% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -99.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 2,068.85% | -128.81% | 429.98% | 21.75% | 33.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 165.68% | 5.25% | 38.06% | 31.59% | -134.05% |